The stock of Premaitha Health PLC (LON:NIPT) is a huge mover today! The stock decreased 1.66% or GBX 0.14 on November 23, hitting GBX 8.36. About 256,043 shares traded hands. Premaitha Health PLC (LON:NIPT) has declined 13.92% since April 25, 2016 and is downtrending. It has underperformed by 19.25% the S&P500.
The move comes after 9 months negative chart setup for the GBX 19.45 million company. It was reported on Nov, 23 by Barchart.com. We have GBX 7.61 PT which if reached, will make LON:NIPT worth GBX 1.75 million less.
Premaitha Health PLC (LON:NIPT) Ratings Coverage
Out of 2 analysts covering Premaitha Health Plc (LON:NIPT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 24 is the highest target while GBX 20 is the lowest. The GBX 22 average target is 163.16% above today’s (GBX 8.36) stock price. Premaitha Health Plc has been the topic of 28 analyst reports since September 22, 2015 according to StockzIntelligence Inc. FinnCap maintained the stock with “Corporate” rating in Thursday, October 27 report. The firm earned “Buy” rating on Monday, October 12 by Panmure Gordon. The stock has “Corporate” rating given by FinnCap on Monday, June 6. The firm earned “Buy” rating on Monday, March 21 by Panmure Gordon. The firm has “Buy” rating given on Monday, December 14 by Panmure Gordon. The stock of Premaitha Health PLC (LON:NIPT) earned “Buy” rating by Panmure Gordon on Tuesday, September 22. Panmure Gordon maintained the shares of NIPT in a report on Wednesday, October 14 with “Buy” rating. The stock has “Corporate” rating given by FinnCap on Monday, April 11. FinnCap maintained the stock with “Corporate” rating in Monday, November 21 report. FinnCap maintained Premaitha Health PLC (LON:NIPT) rating on Friday, September 30. FinnCap has “Corporate” rating and GBX 20 price target.
More news for Premaitha Health PLC (LON:NIPT) were recently published by: Businesswire.com, which released: “Premaitha Health PLC Premaitha Health signs Investment Agreement with Thermo …” on December 14, 2015. Uk.Finance.Yahoo.com‘s article titled: “Premaitha Health PLC (NIPT.L)” and published on July 07, 2014 is yet another important article.
Premaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The company has a market cap of 19.45 million GBP. The Company’s product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house. It currently has negative earnings. The IONA test estimates the risk of a fetus having Down’s syndrome or other serious genetic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.